Update on emerging drug therapies for systemic lupus erythematosus. - Wikidata - awgldk - TriplyDB

Update on emerging drug therapies for systemic lupus erythematosus.

Update on emerging drug therapies for systemic lupus erythematosus.

http://www.wikidata.org/entity/Q37690745

about

Biomarkers for lupus nephritis: a critical appraisal.Anticytokine therapies in systemic lupus erythematosus.Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity.Is there a cure for systemic lupus erythematosus?Update on B-cell targeted therapies for systemic lupus erythematosus.Emerging biological therapies for systemic lupus erythematosus.Current role of rituximab in systemic lupus erythematosus.Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Time trend and risk factors of avascular bone necrosis in patients with systemic lupus erythematosus.A study of hepcidin and monocyte chemoattractant protein-1 in Egyptian females with systemic lupus erythematosus.Treat-to-target in systemic lupus erythematosus: are we there yet?

P2860

Q37736277-1976EB6E-FD7C-423B-9C58-D76D544D512E Q37773296-466F59AB-A0BB-4DBA-BE4B-44AAC7AC7BE7 Q37813704-D1F3D3F3-1AC2-498A-9016-0DC5000F24E7 Q38095888-C6A1C5B5-8DD8-4AEA-B728-F6E97CFBFB8F Q38192656-C96E48FB-408A-4EC3-BA05-05F6E462B592 Q38192683-9AD66CA8-04A6-4441-8F28-A443423917DE Q38293284-8866CFB9-E558-4DEA-B4E8-C05A447158B8 Q38690844-8B2A43CC-F25D-4BEF-AE17-6753A6F97877 Q39199424-F7560E65-7DCC-4ED0-A178-B2CE87F02A0A Q39259180-9F416F1D-A701-4D63-95C4-7988124C7AAA Q47846085-DD2583A8-D792-49AD-8F59-3B0C0CBCE64D

P2860

Update on emerging drug therapies for systemic lupus erythematosus.

http://www.wikidata.org/entity/Q37690745

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Update on emerging drug therapies for systemic lupus erythematosus.

@en

Update on emerging drug therapies for systemic lupus erythematosus.

@nl

type

label

Update on emerging drug therapies for systemic lupus erythematosus.

@en

Update on emerging drug therapies for systemic lupus erythematosus.

@nl

prefLabel

Update on emerging drug therapies for systemic lupus erythematosus.

@en

Update on emerging drug therapies for systemic lupus erythematosus.

@nl

P1433

Q37690745-636523B3-D5EB-41BE-B673-719BA1BA3FEF

P1476

Q37690745-EEA9A7B5-DD5D-47E2-B998-25CEC4E0A13E

P2093

Q37690745-8A3E3939-2739-4435-9BAF-245CC4976DD3

P2860

Q37690745-053AA630-B328-4FF2-9ABE-E8418EF5F9EF

Q37690745-08339107-7441-4778-816A-6D2B7EADB29B

Q37690745-0F2EF852-511C-4D80-8C4A-B66DF0D68570

Q37690745-18272E2A-0371-4FE8-81BA-E69B4C297DA7

Q37690745-199EAD8C-78B7-403D-8F82-F8ED5F2D9A94

Q37690745-1A631ECB-462F-496B-8916-B63641BE9188

Q37690745-1EA1ACBB-B064-48E0-9679-4C4FAA3A3BD6

Q37690745-1EEF3D3E-4F17-41CB-8EC8-FAC0341DD357

Q37690745-1F2BC917-48B3-4CA4-9C0E-904C59FB9F13

Q37690745-21A83E72-5519-4D64-A496-D72DC17210C4

P304

Q37690745-DDAF74FC-2F50-4239-AA06-200F1509FF86

P31

Q37690745-EA2C6DB9-46F2-418E-B969-B6C7400618B9

P356

Q37690745-3A13CA6D-1B27-4CCA-A69C-91FFBA72CFE4

P407

Q37690745-4A3A0FBA-EC77-4586-9694-1CA452FF4177

P433

Q37690745-270B308B-38F5-484F-85B6-0736796AEE7F

P478

Q37690745-CD85A91E-7924-4E58-B240-C2B8A68E7306

P577

Q37690745-32DB1590-7ADB-4634-8BE4-DD3FD1CE0E6D

P698

Q37690745-2FE7490B-3B35-4960-A56D-AB815CBC5E11

P356

14728210903535878

P1433

Expert Opinion on Emerging Drugs

P1476

Update on emerging drug therapies for systemic lupus erythematosus.

@en

P2093

Chi Chiu Mok

http://www.w3.org/2001/XMLSchema#string

P2860

Pathogenesis of systemic lupus erythematosus

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus.

Intravenous immunoglobulin therapy and systemic lupus erythematosus.

Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus.

Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.

Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.

P304

53-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728210903535878

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20148712

http://www.w3.org/2001/XMLSchema#string